Influenza (seasonal)

Sanofi Pasteur Introduces 4-Strain Influenza Vaccine (Fluzone) in Canada

Sanofi Pasteur, the vaccines division of Sanofi, is pleased to announce the launch of its 4-strain influenza vaccine (Fluzone® Quadrivalent) in Canada. This new vaccine was introduced in the United States in 2013 and is quickly becoming the new standard of care for the prevention of influenza. Licensed for use in individuals six months of age and older, Fluzone® Quadrivalent vaccine provides improved protection against influenza, and will be available in Canada starting this flu season.

Gut microbes determine how well the flu vaccine works

Annual flu epidemics cause millions of cases of severe illness and up to half a million deaths every year around the world, despite widespread vaccination programs. A study published by Cell Press on September 11th in Immunity reveals that gut microbes play an important role in stimulating protective immune responses to the seasonal flu vaccine in mice, suggesting that differences in the composition of gut microbes in different populations may impact vaccine immunity.

Pénurie de vaccin pour la grippe annoncée par le fournisseur

Le fournisseur de vaccins contre la grippe GlaxoSmithKline (GSK) annonce qu'il ne pourra pas fournir tous les vaccins commandés par le Canada pour la saison 2014-2015 à cause de problèmes à son usine de Sainte-Foy, à Québec.
Environ 30 % des vaccins, soit environ 2 millions de doses, ne pourront donc être livrés. L'entreprise pharmaceutique devait offrir environ 53 % des vaccins au pays, pour un total de plus de 6 millions de doses.

Nasal Spray Flu Vaccine in Kids Can Trim Caseload And Be Cost-Effective, Especially in a Bad Season, Study Finds

The end of summer means it’s time for the annual flu vaccination. For most adults and children, that will mean a flu shot. But does it have to be? A new study published in the most recent issue of The American Journal of Pharmacy Benefits evaluates the cost-effectiveness of using a nasal spray vaccine for children, who may balk at a shot.

FDA Approves Use of AFLURIA® Influenza Vaccine with PharmaJet’s Needle-Free Injector

PharmaJet® Inc., the developer of a needle-free injection technology to administer medications and vaccines to patients, and bioCSL Inc., the maker of AFLURIA® (Influenza Vaccine) today announced the U.S. Food and Drug Administration (FDA) has approved the PharmaJet Stratis® 0.5mL Needle-Free Jet Injector for delivery of AFLURIA in individuals aged 18 to 64 years. This is the first needle-free delivery system approved by the FDA for the administration of an inactivated influenza vaccine.

10 questions sur les vaccins et la vaccination

Les vaccins, c’est l’enfer ! Entre le carnet de vaccination perdu ou le médecin contacté en urgence qui ignore tout de notre situation, on ne sait plus vraiment où l’on en est dans notre calendrier de vaccins… Et si on mettait le nez dedans une bonne fois pour toute au lieu de laisser les choses s’enliser ?
Mon dernier vaccin date du collège, je dois faire lequel ?

Vaccination contre la grippe saisonnière : bénéfice modéré du vaccin Fluenz Tetra® par rapport au vaccin Fluenz

Dans le cadre de la procédure de mise sur le marché du vaccin grippal Fluenz Tetra®, fabriqué par le laboratoire MedImmune, le Haut Conseil de la santé publique (HCSP) a récemment publié des recommandations sur la place de ce vaccin dans la stratégie vaccinale de prévention de la grippe saisonnière en France.

Sanofi Pasteur Announces Publication of Positive Data for Fluzone High-Dose Vaccine in the New England Journal of Medicine

Sanofi Pasteur, the vaccines division of Sanofi, today announced that The New England Journal of Medicine published positive results from a large-scale, multi-center efficacy trial, which found that Fluzone® High-Dose (Influenza Vaccine) was more efficacious in preventing influenza (“the flu”) in adults 65 years of age and older compared to standard-dose Fluzone vaccine.

Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine For Upcoming 2014-2015 Season In United States

Sanofi Pasteur, the vaccines division of Sanofi, announced today that the first lots of Fluzone® (Influenza Vaccine) for the 2014-2015 influenza (“the flu”) season have been released by the U.S. Food and Drug Administration (FDA) for distribution. The lots were shipped on July 21, 2014, representing the first of at least 65 million doses of seasonal influenza vaccine manufactured by Sanofi Pasteur that will be delivered to U.S. health care providers and pharmacies in August.